Evaluation of midkine and anterior gradient 2 in a multimarker panel for the detection of ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 29, Issue 1, 2010, Pages

  Rice, Gregory E ^a   Edgell, Tracey A ^a   Autelitano, Dominic J ^a  

^a HealthLinx Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; MIDKINE; TUMOR MARKER; UNCLASSIFIED DRUG; AGR2 PROTEIN, HUMAN; CYTOKINE; MEMBRANE PROTEIN; MUC16 PROTEIN, HUMAN; PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CLASSIFICATION; CLASSIFICATION ALGORITHM; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; NORMAL HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SENSITIVITY AND SPECIFICITY; STOCHASTIC MODEL; ADENOCARCINOMA; BLOOD; CASE CONTROL STUDY; COLLOID CARCINOMA; COMPARATIVE STUDY; CYSTADENOCARCINOMA; ENDOMETRIUM TUMOR; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AREA UNDER CURVE; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CYSTADENOCARCINOMA, SEROUS; CYTOKINES; ENDOMETRIAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS; RETROSPECTIVE STUDIES;

EID: 77953017030     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-29-62     Document Type: Article

References (46)

1. Ovarian cancer screening: are we making any progress? PJ Paley, Curr Opin Oncol 2001 13 399 402 10.1097/00001622-200109000-00015 11555720
2. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? V Nossov M Amneus F Su J Lang JMT Janco ST Reddy R Farias-Eisner, American Journal of Obstetrics and Gynecology 2008 199 215 223 10.1016/j.ajog.2008.04.009 18468571
3. Progress and challenges in screening for early detection of ovarian cancer. IJ Jacobs U Menon, Molecular & Cellular Proteomics 2004 3 355 366 10.1074/mcp.R400006-MCP200 (Pubitemid 38702089)
4. Serum multimarker assay for early diagnosis of ovarian cancer. AE Lokshin Z Yurkovetsky R Bast A Lomakin GL Maxwel AK Godwin, Gynecologic Oncology 2008 108 113 S114
5. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. GP Bertenshaw P Yip P Seshaiah J Zhao TH Chen WS Wiggins JP Mapes BC Mansfield, Cancer Epidemiology, Biomarkers & Prevention 2008 17 2872 2881 10.1158/1055-9965.EPI-08-0464
6. Validation of serum biomarkers for detection of early-stage ovarian cancer. V Nosov F Su M Amneus M Birrer T Robins J Kotlerman S Reddy R Farias-Eisner, American Journal of Obstetrics and Gynecology 2009 200 19111277
7. A large-scale multi-center independent validation study of a panel of seven biomarkers for the detection of ovarian cancer. Z Zhang RC Bast I Vergote C Hogdall FR Ueland A Van der Zee Z Wang C Yip DW Chan ET Fung, Journal of Clinical Oncology 2006 24 269S 269S
8. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. T Edgell G Martin-Roussety G Barker DJ Autelitano D Allen P Grant GE Rice, J Cancer Res Clin Oncology 2010
9. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. E Gorelik DP Landsittel AM Marrangoni F Modugno L Velikokhatnaya MT Winans WL Bigbee RB Herberman AE Lokshin, Cancer Epidemiol Biomarkers Prev 2005 14 981 987 10.1158/1055-9965.EPI-04-0404 15824174
10. Diagnostic markers for early detection of ovarian cancer. I Visintin Z Feng G Longton DC Ward AB Alvero Y Lai J Tenthorey A Leiser R Flores-Saaib H Yu, et al. Clin Cancer Res 2008 14 1065 1072 10.1158/1078-0432.CCR-07-1569 18258665
11. Increased plasma concentrations of anterior gradent 2 protein are positively associated with ovarian cancer. TA Edgell DL Barraclough A Rajic J Dhulia KJ Lewis JE Armes R Barraclough PS Rudland GE Rice DJ Autelitano, Clin Sci (Lond) 2010 20136634
12. Phases of biomarker development for early detection of cancer. MS Pepe R Etzioni Z Feng JD Potter ML Thompson M Thornquist M Winget Y Yasui, J Natl Cancer Inst 2001 93 1054 1056 10.1093/jnci/93.14.1054 11459866
13. Use of ranks in one-criterion variance analysis. WH Kruskal WA Wallis, Journal of the American Statistical Association 1952 47 583 621 10.2307/2280779
14. Multiple comparisons using rank sums. OJ Dunn, Technometrics 1964 6 241 10.2307/1266041
15. IH Witten E Frank, Data Mining: Practical machine learning tools and techniques Morgan Kaufmann 2005: San Francisco 2 2005
16. The WEKA Data Mining Software: An Update; SIGKDD Explorations. M Hall E Frank G Holmes B Pfahringer P Reutemann IH Witten, SIGKDD Explorations 2009 11
17. On the scalability of ordered multi-class ROC analysis. W Waegeman B De Baets L Boullart, Computational Statistics & Data Analysis 2008 52 3371 3388 10.1016/j.csda.2007.12.001
18. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. JA Hanley BJ McNeil, Radiology 1983 148 839 843 6878708
19. Additive logistic regression: A statistical view of boosting. J Friedman T Hastie R Tibshirani, Annals of Statistics 2000 28 337 374 10.1214/aos/ 1016218223
20. Serum levels of midkine, a heparin-binding growth factor, increase in both malignant and benign gynecological tumors. RMH Salama H Muramatsu H Kobayashi S Nomura M Shigehiko T Muramatsu, Reprod Immunol Biol 2006 21 64 70 10.3192/jsirib.21.64
21. Biomarkers for cardiovascular disease: challenges and future directions. A May TJ Wang, Trends Mol Med 2008 14 261 267 10.1016/j.molmed.2008.04.003 18487087
22. Identification of a new heparin-binding protein localized within chick basement-membranes. M Vigny D Raulais N Puzenat D Duprez MP Hartmann JC Jeanny Y Courtois, European Journal of Biochemistry 1989 186 733 740 10.1111/j.1432-1033.1989.tb15267.x 2558016
23. A retinoic acid responsive gene, mk, produces a secreted protein with heparin binding-activity. M Tomomura K Kadomatsu M Nakamoto H Muramatsu H Kondoh K Imagawa T Muramatsu, Biochemical and Biophysical Research Communications 1990 171 603 609 10.1016/0006-291X(90)91189-Y 2403350
24. Midkine, a heparin-binding growth factor: Its discovery and functions. K Kadomatsu, Seikagaku-Journal of Japanese Biochemical Society 1998 70 1315 1325
25. Midkine, a retinoic acid-inducible growth-differentiation factor-immunochemical evidence for the function and distribution. H Muramatsu H Shirahama S Yonezawa H Maruta T Muramatsu, Developmental Biology 1993 159 392 402 10.1006/dbio.1993.1250 8405666
26. Midkine and pleiotrophin expression in normal and malignant breast-tissue. RI Garver DM Radford H Doniskeller MR Wick PG Milner, Cancer 1994 74 1584 1590 10.1002/1097-0142(19940901)74:5<1584:AID-CNCR2820740514>3.0. CO;2-V 7520350
27. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. R Choudhuri HT Zhang S Donnini M Ziche R Bicknell, Cancer Research 1997 57 1814 1819 9135027
28. A receptor-like protein-tyrosine phosphatase PTP zeta/RPTP beta binds a heparin-binding growth factor midkine-Involvement of arginine 78 of midkine in the high affinity binding to PTP zeta. N Maeda K Ichihara-Tanaka T Kimura K Kadomatsu T Muramatsu M Noda, Journal of Biological Chemistry 1999 274 12474 12479 10.1074/jbc.274.18.12474 10212223
29. Haptotactic migration induced by midkine-Involvement of protein-tyrosine phosphatase xi, mitogen-activated protein kinase, and phosphatidylinositol 3-kinase. MS Qi S Ikematsu N Maeda K Ichihara-Tanaka S Sakuma M Noda T Muramatsu K Kadomatsu, Journal of Biological Chemistry 2001 276 15868 15875 11340082
30. Mice doubly deficient in the midkine and pleiotrophin genes exhibit deficits in the expression of beta-tectorin gene and in auditory response. P Zou H Muramatsu M Sone H Hayashi T Nakashima T Muramatsu, Laboratory Investigation 2006 86 645 653 10.1038/labinvest.3700428 16619002
31. Midkine inhibits caspase dependent apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase in cultured neurons. K Owada N Sanjo T Kobayashi H Mizusawa H Muramatsu T Muramatsu M Michikawa, Journal of Neurochemistry 1999 73 2084 2092 10537068
32. Increased expression of midkine in the rat colon during healing of experimental colitis. T Yuki S Ishihara MAK Rumi CF Ortega-Cava Y Kadowaki H Kazumori N Ishimura Y Amano N Moriyama Y Kinoshita, American Journal of Physiology-Gastrointestinal and Liver Physiology 2006 291 735 G743 10.1152/ajpgi.00388.2005 16959957
33. Midkine, a heparin-binding growth factor, is fundamentally involved in the pathogenesis of rheumatoid arthritis. K Maruyama H Muramatsu N Ishiguro T Muramatsu, Arthritis and Rheumatism 2004 50 1420 1429 10.1002/art.20175 15146411
34. A defect in cell-to-cell adhesion via integrin-fibronectin interactions in a highly metastatic tumor cell line. Y Abe T Tsutsui J Mu A Kosugi H Yagita K Sobue O Niwa H Fujiwara T Hamaoka, Japanese Journal of Cancer Research 1997 88 64 71 9045898
35. Expression of midkine and pleiotropin in ovarian tumors. T Nakanishi K Kadomatsu T Okamoto Y Tomoda T Muramatsu, Obstetrics and Gynecology 1997 90 285 290 10.1016/S0029-7844(97)00237-8 9241309
36. Midkine as a novel target for antibody therapy in osteosarcoma. H Maehara T Kaname K Yanagi H Hanzawa I Owan T Kinjou K Kadomatsu S Ikematsu T Iwamasa F Kanaya K Naritomi, Biochemical and Biophysical Research Communications 2007 358 757 762 10.1016/j.bbrc.2007.04.183 17506984
37. Abnormal expression, highly efficient detection and novel truncations of midkine in human tumors, cancers and cell lines. P Tao DH Xu SB Lin GL Ouyang YD Chang Q Chen YY Yuan XM Zhuo QC Luo J Li, et al. Cancer Letters 2007 253 60 67 10.1016/j.canlet.2007.01.019 17379400
38. Plasma midkine level is a prognostic factor for human neuroblastoma. S Ikematsu A Nakagawara Y Nakamura M Ohira M Shinjo S Kishida K Kadomatsu, Cancer Science 2008 99 2070 2074 19016768
39. Identification of genes with differential expression in acquired drug-resistant gastric cancer cells using high-density oligonucleotide microarrays. HC Kang IJ Kim JH Park Y Shin JL Ku MS Jung BC Yoo HK Kim JG Park, Clinical Cancer Research 2004 10 272 284 10.1158/1078-0432.CCR-1025-3 14734480
40. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. DA Thompson RJ Weigel, Biochemical and Biophysical Research Communications 1998 251 111 116 10.1006/bbrc.1998.9440 9790916
41. hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumors and interact with metastasis gene C4.4a and dystroglycan. GC Fletcher S Patel K Tyson PJ Adam M Schenker JA Loader L Daviet P Legrain R Parekh AL Harris JA Terrett, British Journal of Cancer 2003 88 579 585 10.1038/sj.bjc.6600740 12592373
42. Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. D Liu PS Rudland DR Sibson A Platt-Higgins R Barraclough, Cancer Research 2005 65 3796 3805 10.1158/0008-5472.CAN-04-3823 15867376
43. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. RT Marquez KA Baggerly AP Patterson JS Liu R Broaddus M Frumovitz EN Atkinson DI Smith L Hartmann D Fishman, et al. Clinical Cancer Research 2005 11 6116 6126 10.1158/1078-0432.CCR-04-2509 16144910
44. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. V Ramachandran T Arumugam HM Wang CD Logsdon, Cancer Research 2008 68 7811 7818 10.1158/0008-5472.CAN-08- 1320 18829536
45. Global gene expression profiling of circulating tumor cells. DA Smirnov DR Zweitzig BW Foulk MC Miller GV Doyle KJ Pienta NJ Meropol LM Weiner SJ Cohen JG Moreno, et al. Cancer Research 2005 65 4993 4997 10.1158/0008-5472.CAN-04- 4330 15958538
46. Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. M Valladares-Ayerbes S Diaz-Prado M Reboredo V Medina P Iglesias-Diaz MJ Lorenzo-Patino RG Campelo MH Tch IS Tch LM Anton-Aparicio, Cancer Detection and Prevention 2008 32 236 250 10.1016/j.cdp.2008.08.002 18801625